Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037031 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
A Phase 1 study of Renal Impairment, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 6
- Study locations
NCT06037031 is a Phase 1 study of Renal Impairment that has completed, run by Pfizer. The registered enrollment target is 16 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT06037031, a Phase 1 study of Renal Impairment, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level of loss of kidney function may process PF-07923568 differently from healthy people. PF-07923568 is developed as a possible treatment for respiratory syncytial virus (RSV) infection. RSV is a common virus that affects the lungs and usually causes mild, cold-like symptoms. RSV can cause severe lung infections in infants, elderly, and adults with other serious medical conditions. This study is seeking participants who: * Have less than 25% difference in kidney function between 2 screening visits. * Meet the eGFR criteria for being assigned to groups. eGFR tells how well the kidney is filtering. * Are not on hemodialysis. Hemodialysis is a type of treatment that helps the body remove extra fluid and waste products from the blood when the kidneys are not able to. Participants will take the study medicine as capsules by mouth once at the study clinic. The participants will stay at the study clinic for about 5 days. During that time, the study team will monitor the participants. The study team will take some blood samples to test the level of PF-07923568. This will help us understand if some level of loss of kidney function will have an effect on the study medicine PF-07923568.
Conditions Studied
Interventions
- DRUG Drug: PF-07923568
Study Locations (6)
Texas
- Clinical Trials of Texas, LLC - San Antonio
- Clinical Trials of Texas, LLC dba Flourish Research - San Antonio
- Clinical Trials of Texas, LLC - San Antonio
Florida
- Orlando Clinical Research Center - Orlando
- Genesis Clinical Research, LLC - Tampa
Minnesota
- Prism Research LLC dba Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06037031
The ClinicalTrials.gov registry entry for NCT06037031 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Drug: PF-07923568 is the first listed.
NCT06037031 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Texas, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06037031 about?
NCT06037031 is a clinical study titled "A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function". The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level of loss of kidney function may process PF-07923568 differently from healthy people. PF-07923568 is developed as a possible treatment for respiratory syn...
What is the current status of trial NCT06037031?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-30. Estimated completion is 2024-07-03.
What conditions does trial NCT06037031 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT06037031?
The interventions under investigation include: Drug: PF-07923568 (DRUG).
Who is sponsoring clinical trial NCT06037031?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06037031 being conducted?
This trial has 6 study locations across Florida, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.